Bioequivalence study of two enteric-coated formulations of pantoprazole in healthy volunteers under fed conditions

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 9, 2008, Pages 451-456

  Filipe, Augusto ^a   Almeida, Susana ^a,b   Spínola, Ana Cristina Franco ^a   Neves, Rita ^a   Trabelsi, Fethi ^c   Torns, Alex ^d   Shink, Eric ^c  

^a Tecnimede Group   (Portugal)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Anapharm Canada   (Canada)

^d Anapharm Europe SL   (Spain)

Author keywords

CAS 102625 70 7; Pantoprazole, bioequivalence, pharmacokinetics; Proton pump inhibitors

Indexed keywords

PANTOPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NORMAL HUMAN; PAIN; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT;

EID: 53649098781     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296538     Document Type: Article

References (15)

1. Jungnickd PW Pantoprazole: A New Proton Pump Inhibitor. Clin Ther. 2000;22(11):1260-1293.
2. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003;63(1):101-132.
3. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet. 2000 Mar; 38(3):243-270.
4. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, et al. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Clin Pharmacol Ther. 2001;69:108-113.
5. Boparai V, Rajagopalan J and Triadafilopoulos G. Guide to the Use of Proton Pump Inhibitors in Adult Patients. Drugs. 2008;68(7):925-947.
6. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98. July 2001.
7. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on modified release oral and transdermic dosage forms: section II (pharmacokinetic and clinical evaluation). CPMP/EWP/280/96. July 1999.
8. Data on file, Medical Department, Grupo Tecnimede, Portugal, 2007.
9. Good Clinical Practice Consolidated Guideline. International Conference on Harmonisation, E6. 1996.
10. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on modified release oral and transdermic dosage forms: section II (pharmacokinetic and clinical evaluation). CPMP/EWP/280/96. July 1999.
11. Guidance on pantoprazole sodium. Food and Drug Administration (FDA), May 2008.
12. Center for Drug Evaluation and Research (CDER) - Food and Drug Administration (FDA). Guidance for industry: food-effect bioavailability and fed bioequivalence studies. December 2002.
13. de Campos DR, Vieira NR, Bernasconi G, Barros FA, Meurer EC, Marchioretto MA, et al. Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions. Arzneimittel-Forschung (Drug Research). 2007;57(6):309-314.
14. Mendes FD, Patni AK, Reyer S, Monif T, Moreira LD, Ilha JO, et al. Comparative bioavailability study with two pantoprazole delayed-released tablet formulations administered with and without food in healthy subject. A Arzneimittel-Forschung (Drug Research). 2008;58(3):141-148.
15. CHMP Efficacy Working Party: Therapeutic Subgroup on Pharmacokinetics. Questions and Answers on the Bioavailability and Bioequivalence Guideline. EMEA/CHMP/EWP/40326/2006.